Search
Refine your search
916 results found
Smart & Biggar is Canada's largest firm practising exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montreal…
Smart & Biggar | Canada | 12 Apr 2021
No more chasing rainbows: advantages of black and white when filing Canadian trademark applications
Some foreign brand owners may be surprised to learn that in Canada, when seeking to protect design (or figurative) marks, it is sometimes better to…
Smart & Biggar | Canada | 5 Apr 2021
Patentability of diagnostic methods - has the Patent Office drawn the line?
The COVID-19 pandemic has highlighted the importance of medical diagnostic technologies. The media frequently reports on matters of…
Smart & Biggar | Canada | 31 Mar 2021
Federal Court of Appeal affirms prohibition order against Apotex regarding abiraterone
As previously reported, in the final decision released under the pre-amended Patented Medicines (Notice of Compliance) Regulations (Regulations), the…
Smart & Biggar | Canada | 31 Mar 2021
Health Canada Consultation on Electronic Media in Prescription Drug Labelling
On March 12, 2021, Health Canada released for consultation its new Draft Guidance Document on Electronic media in prescription drug labelling. The…
Smart & Biggar | Canada | 30 Mar 2021
PMPRB Updates: Definition of “Gap Medicine” amended, modified threshold for investigating the price of new patented medicines
On March 17, 2021 the Patented Medicine Prices Review Board (PMPRB) announced the result of the Consultation opened in January…
Smart & Biggar | Canada | 30 Mar 2021
Federal Court denies stay of decision issuing NOC for RUZURGI
On September 30, 2020, the Federal Court dismissed an application by Catalyst Pharmaceuticals Inc (Catalyst) and KYE Pharmaceuticals Inc (KYE)…
Smart & Biggar | Canada | 30 Mar 2021
Federal Court of Appeal upholds Federal Court decision finding Shire’s VYVANSE patent valid
The Federal Court of Appeal (FCA) recently dismissed an appeal by Apotex from a decision of the Federal Court (see our article here) holding that the…
Smart & Biggar | Canada | 30 Mar 2021
Ontario Superior Court dismisses Apotex’s Statutes of Monopolies and Trademarks Act claims regarding olanzapine
On March 8, 2021, the Ontario Superior Court of Justice granted Eli Lilly's (Lilly) motion for summary judgment and dismissed Apotex's claims under…
Smart & Biggar | Global | 29 Mar 2021
Protecting innovations through patent due diligence and FTO analysis
Innovations that arise in competitive markets with a well-developed and rapidly evolving IP space often integrate several pre-existing Technologies…
Smart & Biggar | Canada | 29 Mar 2021
New CADTH Report on Health Technology Trends in 2021
The Canadian Agency for Drugs and Technologies in Health (CADTH) published an interesting new report on January 29, 2021 about Health Technology…
